APPlexus is an initiative designed to address educational needs specific to advanced practice providers who care for patients with cancer. These webinars will navigate insights and updates across several cancer types and deliver innovative, real-time education to nurse practitioners and physician associates worldwide. Our mission is to bridge knowledge gaps, untangle controversies, and spotlight pivotal data in a digestible and engaging format.
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.
May
182024
8:00 AM - 1:20 PM Eastern Time (ET)
Virtual
Advanced Practice Provider
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio
Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona
Tucson, Arizona
Advanced Practice Provider
Physician Assistant
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania
There are no fees required to participate in this activity.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.
Target Audience
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.
Advances in Targeted Therapeutics for Biliary Tract Cancer
Goal Statement
To improve the knowledge, confidence, and skills of NPs/PAs who care for patients with biliary tract cancer on the latest updates in guideline-directed evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes for their patients.
Learning Objectives
BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma.
Learning Objectives
Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies
Goal Statement
The goal of this program is to improve the knowledge and competence of learners to safely and effectively integrate bispecific antibody therapy into practice to optimize patient outcomes.
Learning Objectives
Next-Generation Care for Patients With Bladder Cancer
Goal Statement
To improve the knowledge, confidence, and skills of NPs/PAs who care for patients with bladder cancer on the latest updates in guideline-directed and evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes for their patients.
Learning Objectives
Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Bladder Cancer.
Learning Objectives
BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Advances in Targeted Therapeutics for Biliary Tract Cancer
Next-Generation Care for Patients With Bladder Cancer
Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours, including 3.0 hours of pharmacotherapy credit.
Physician Associate Continuing Medical Education
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 3.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.
Advances in Targeted Therapeutics for Biliary Tract Cancer
Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Provided by Clinical Care Options, LLC in partnership with Partners for Advancing Clinical Education (PACE) and Practicing Clinicians Exchange, LLC.
Supported by an educational grant from Sanofi Genzyme.
Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies
Provided by Clinical Care Options, LLC in partnership with Partners for Advancing Clinical Education (PACE) and Practicing Clinicians Exchange, LLC.
Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Next-Generation Care for Patients With Bladder Cancer
Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC
Supported by an educational grant from Merck Sharp & Dohme LLC.
Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC
Supported by an educational grant from Merck Sharp & Dohme LLC.